Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...

A quiet hope has started to grow among people living with stubborn cholesterol problems as researchers report early success ...

Crispr ( CRSP) is said to have attracted takeover interest, according to traders, who cited a Betaville "uncooked' alert that ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

Earlier this month, CRISPR Therapeutics announced positive Phase 1 data for its investigational in vivo CRISPR/Cas9 therapy CTX310, which showed substantial and durable reductions in key lipid levels ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...